Fig. 2: Time to vital organ deterioration or mortality in the intent-to-treat population. | Leukemia

Fig. 2: Time to vital organ deterioration or mortality in the intent-to-treat population.

From: A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis

Fig. 2

a Time to vital organ deterioration or mortality (investigator assessed)—defined as time from randomization to vital organ (heart or kidney) deterioration (evaluated according to central laboratory results and International Society of Amyloidosis criteria) or death, whichever occurred first. Cardiac deterioration was defined as the need for hospitalization for heart failure. Kidney deterioration was defined as progression to end-stage renal disease with the need for maintenance dialysis or renal transplantation. Patients without documentation of organ deterioration or death were censored at the date of the last assessment. b Time to vital organ deterioration and mortality by randomization stratification factors (investigator assessed). CI confidence interval, HR hazard ratio, NE not estimable.

Back to article page